

Translate Bio readies IPO

04 June 2018 | News

The clinical-stage biotech creates messenger RNA (mRNA) to encode functional proteins for therapeutic uses.



Singapore-Lexington, MA-based Translate Bio (TBIO) has filed a prospectus for its U.S. IPO.

The clinical-stage biotech creates messenger RNA (mRNA) to encode functional proteins for therapeutic uses. The company says its mRMA is delivered to the target cell where the cell's own machinery recognizes it, translates it and restores/improves protein function to treat or prevent disease.

Lead candidate is Phase 1/2-stage MRT5005, an inhaled treatment for cystic fibrosis (CF) designed to deliver mRNA encoding fully functional CFTR protein to the lung. It is designed to treat all CF patients regardless of their underlying genetic mutation.